LungCancerEu Profile Banner
Lung Cancer Europe Profile
Lung Cancer Europe

@LungCancerEu

Followers
2K
Following
11K
Media
1K
Statuses
5K

LuCE is the voice of people affected by lung cancer in Europe, advocating and networking to improve outcomes for the community. #LungCancer #LCSM

Europe
Joined December 2016
Don't wanna be here? Send us removal request.
@LungCancerEu
Lung Cancer Europe
1 day
A new Lancet Oncology article sets out a strong case for risk-based #lungcancer screening in Europe, showing higher detection & better targeting than traditional criteria. For Lung Cancer Europe, this supports our call for screening approaches that improve early diagnosis &
0
1
7
@LungCancerEu
Lung Cancer Europe
3 days
🆕 study: #lungcancer risk increases when real-world pollution exposures overlap - traffic, indoor air & second-hand smoke - & the risk is higher in people with genetic susceptibility. Source: Nature Portfolio (Dec 2025). https://t.co/SRjB2bXlDa #LCSM #AirPollution
0
6
12
@WalceOnlus2006
WALCE APS
1 day
🇬🇧📍 Continued throughout 2025, EPROPA (European Program for ROutine testing of Patients with Advanced Lung Cancer) is a support program designed and promoted by WALCE (Women Against Lung Cancer in Europe)
1
1
2
@OncogeneCancer
Oncogene Cancer Research
2 days
Angus Pratt was unforgettable - his @TheWRP4LC white ribbon, red toque and dry humour lit up every many conferences & events. After navigating breast cancer as a man & later EGFR LC, he found a real kinship with the #lungcancer community. He leaves a big mark on our hearts. #LCSM
1
4
21
@LCN_UK
Lung Cancer Nursing UK
1 day
Our Annual Award 2026 is now open! LCNUK Members can showcase projects improving care for people with lung cancer or mesothelioma. A £1,500 award is available. Submit your proposal https://t.co/necegzfSxl
0
3
4
@LungConnectIN
Lung Connect India
2 days
Our newsletter is here! Dive into inspiring stories, helpful resources, and meaningful updates that bring our community closer and keep you informed. Read full newsletter- https://t.co/xP9ZaKX8ON #lungconnect #LungHealth #lungcancer #lungcancerawareness #newsletter
0
3
3
@dplanchard
d.planchard
2 days
T-cell engagers in SCLC: efficacy, toxicities, and so many trials ongoing... Making these T-Cell therapies deliverable in all hospitals is not so straightforward, especially with CRS management. Great insights by @DrSanjayPopat @myESMO #ESMOpreceptorship2025
1
9
25
@LungCancerEu
Lung Cancer Europe
1 day
A new Lancet Oncology article sets out a strong case for risk-based #lungcancer screening in Europe, showing higher detection & better targeting than traditional criteria. For Lung Cancer Europe, this supports our call for screening approaches that improve early diagnosis &
0
1
7
@JordiRemon
Jordi Remon
3 days
Selective TKIs are the mainstay Ttx for most fusions. Current challenges: availability of multiple competitive options, how to sequence and access. In absence of predictive biomarkers: CNS activity and toxicity are relevant. Role of upfront CT + TKI in fusion+ NSCLC remains uk
0
8
33
@LCN_UK
Lung Cancer Nursing UK
2 days
LCNUK Small Grants Scheme is now open for 2026! Members can apply for up to £5,000 to support research, evaluation or audit projects that improve lung cancer nursing practice. Start your application today 📅 https://t.co/5zdTBj4h4n
0
3
6
@SWOG
SWOG Cancer Research Network
2 days
S2409 (the PRISM trial) is a study for people with extensive stage small cell lung cancer (ES-SCLC). The goal is to match different #SCLC subtypes with the best treatment. Visit https://t.co/JK0Y59hyUJ. Or call 1-800-4-CANCER. #LCSM
0
6
7
@OncogeneCancer
Oncogene Cancer Research
4 days
Logan, diagnosed with stage 4 ALK+ #lungcancer age 32, thought he was protecting his son until this moment. Be sure to watch the full interview to learn about how hard it was to get diagnosed and how he’s supporting others. 🎙️ https://t.co/7Fk4ZjyJXK #LCSM
0
3
10
@DrewMoghanaki
Drew Moghanaki
2 days
Jill Feldman recognized by @ellakaz for her service on the American Cancer Society’s National Lung Cancer Roundtable steering committee. 🫁 #NLCRT2025
0
5
19
@LungCancerEu
Lung Cancer Europe
3 days
🆕 study: #lungcancer risk increases when real-world pollution exposures overlap - traffic, indoor air & second-hand smoke - & the risk is higher in people with genetic susceptibility. Source: Nature Portfolio (Dec 2025). https://t.co/SRjB2bXlDa #LCSM #AirPollution
0
6
12
@NReguart
Noemi Reguart
3 days
Brilliant talk by Prof. Pan-Chyr Yang on air pollution, genetics, lung cancer, and screening in Asia at the #ESMOPreceptorshipAsia. @myESMO
0
4
20
@DrewMoghanaki
Drew Moghanaki
3 days
New reality for lung cancer screening. By @ellakaz https://t.co/AeG8IUdF3b
0
1
6
@JordiRemon
Jordi Remon
5 days
Elironrasib, a new RAS(ON) inh. In KRAS (OFF)G12C mut preTtx NSCLC: Good ORR and PFS as monotherapy.Hvr, impact of comutations on efficacy & not reported 🧠 activity. Crowded space in 1L 🤯: monoTtx vs combination KRASi + Chemo (+/-IO), SHP2i, antiEGFR… othrs. #ESMOSIA25
0
11
40
@dplanchard
d.planchard
3 days
Very clear and comprehensive presentation on perioperative TKIs by @HHorinouchi Still many questions, but osimertinib has revolutionized the approach (ADAURA), as it continues to do for EGFRmut advanced stage (FLAURA and FLAURA2 are both the standard of care 1st line).@myESMO
0
5
20
@LungCancerEu
Lung Cancer Europe
4 days
Jade joined the European Health Summit this week to bring her lived experience of #lungcancer into a high-level roundtable with the @WHO, the @EU_Commission and the Cancer Mission. She spoke about early detection, missed signs & how AI in imaging could help. She also highlighted
0
1
9